Summary
- IN8bio has filed to raise $86.25 million in an IPO of its common stock.
- The firm is developing treatments for various blood cancers.
- INAB is in Phase 1 safety trials for its two lead programs, though management hasn't provided any commentary on results to-date.
- Looking for more investing ideas like this one? Get them exclusively at IPO Edge. Get started today »
Quick Take
IN8bio (INAB) has filed to raise $86.25 million in an IPO of its common stock, according to an S-1 registration statement.
The firm is developing treatment candidates for blood cancers.
INAB is the first firm to trial genetically modified gamma-delta T cells.
When we learn more about the IPO, I’ll provide a final opinion.
Company & Technology
New York, New York-based IN8bio was founded to advance a pipeline of treatment options for glioblastoma [GBM] and acute leukemia using 'allogeneic, autologous and genetically modified gamma-delta T cells.The advantage of employing gamma-delta T cells is that they kill cancer cells 'while possessing a tumor recognition mechanism that protects healthy tissue.'
Management is headed by co-founder, president, CEO and CFO William Ho, who was previously founder and Managing Partner at AlephPoint Capital, a healthcare venture capital firm.
Below is a brief overview video of glioblastoma:
